Category Archives: Biotech stocks

Biostem U.S. Corp. HAIR

I’m on fire about Biostem U.S. Corp. (HAIR) today and the reason is in the ticker itself.

HAIR uses ethically harvested adult stem cells to super-charge balding scalps.

They say it’s virtually painless and you can do it on your lunch break.

You can imagine how much cash an outpatient cure for baldness would pull in!

And yet somehow HAIR is currently priced in the 20 cent range, so everyman traders like us still have a chance to see it on the ground floor.

See, HAIR is only now rolling its stem cell technique into hair transplant clinics in places like Orlando, Florida, where aging big shots want to stay young-looking forever.

HAIR will receive monthly revenue from each doctor who signs up.

Because they’re starting from near-zero here, every dollar moves the valuation needle.

And those first clinics just opened for stem cells a few weeks ago, so the inflection point here is as fresh as it gets!

Now that the wheels have finally started turning, HAIR could even become an attractive Big Biotech merger target.

After all, Propecia brings down $400 million a year for Merck.

And old Rogaine earned its maker $150 million a year back in the 90s.

The market is endless. Look for baldness cure online, 3 MILLION hits.

Just a few months ago, news that they’d found the cause of baldness drove the world wild.

A cure in five years? HAIR is already doing it!

HAIR is also turning heads as brokerage firms throw it cash for the privilege of getting their taste of this story before the Street catches on.

Elco Securities bought 20 million HAIR shares back in May at 25 cents apiece.

That’s a 65% premium over where HAIR was trading the day the deal was signed.

Remember, HAIR is now well under the $0.25 level so that position is still technically deep underwater.

Did the big boys at Elco get taken here or did they figure that $5 MILLION bet will be worth a lot more down the road?

All I know is that HAIR plans to use that cash to keep the lights on while its marketing team goes to work!

This board is stacked with top management from blue-chip corporations like Crocs.

Love or hate the shoes, Stephen Beck and Scott Crutchfield know how to build a multi-billion-dollar craze from the ground up, and they seem eager to do it again.

Bottom Line: HAIR just blasted out of the gate with a new revenue model and some of the biggest names in hair replacement on its team.

Smart players have gambled long green on this company and its technology.

Resources:
http://finance.yahoo.com/q?s=HAIR
http://www.google.com/finance?q=PINK%3AHAIR
http://ih.advfn.com/p.php?pid=squotesymbol=HAIR

Share This:

Companies in the Biotech industry to watch: PWRM, ABCO, and ENCO

Power3 Medical Products, Inc. – (OTC.BB: PWRM) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

PWRM is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.

Skymark Research, a leading provider of small- and micro-cap independent investment research, recently initiated coverage on PWRM. Also on July 12 in Honolulu, Hawaii Power 3 will be presenting four abstracts to this annual meeting of the International Congress of Alzheimer’s Disease. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro® AD biomarkers and blood test for Alzheimer’s disease. The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

For more information visit www.power3medical.com.

—————————————————–

The Advisory Board Company – (NasdaqGS: ABCO) provides best practices research, analysis, executive education and leadership development, business intelligence software tools, and installation support services primarily to the health care industry. Its programs focus on business strategy, operations, and general management issues.

Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, recently initiated coverage on ABCO.

The Advisory Board strides to proceeds in the belief that organizations in certain sectors—health care, education, and government among them—have a charter above commerce, but preserving this higher calling requires an unyielding insistence on improvement. Their mission is to surface and secure economies of intellect on behalf of member organizations—discerning “True North,” communicating these insights and best practices with clarity, and providing innovative services such that our members can set compass and elevate performance accordingly.

ABCO proceeds in the belief that organizations in certain sectors—health care, education, and government among them—have a charter above commerce, but preserving this higher calling requires an unyielding insistence on improvement. Our mission is to surface and secure economies of intellect on behalf of member organizations—discerning “True North,” communicating these insights and best practices with clarity, and providing innovative services such that our members can set compass and elevate performance accordingly.

Keep researching at http://www.advisoryboardcompany.com

——————————————————

Encorium Group, Inc. – (NasdaqCM: ENCO) designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The company’s clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development.

ENCO announced that the company filed a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) for a proposed rights offering to its existing stockholders. The proposed rights offering would be made through the distribution of subscription rights to purchase up to $10 million of the company’s shares of common stock, par value $0.001 per share, on the terms and conditions and at a price determined by a special committee of the company’s board of directors.

Chief Executive Officer, Dr. Kai Lindevall said, “The proposed rights offering is designed to provide additional working capital and liquidity to the Company by giving each stockholder a chance to buy additional shares and the opportunity to avoid dilution of their ownership interests.”

Members of the company are just returning from the annual European Vaccine Forum in Barcelona, which took place from June 21-23

Share This:

22nd Century Group (NYSEMKT:XXII)

22nd Century Group (NYSEMKT:XXII)

22nd Century Group (NYSEMKT:XXII) is a generally underfollowed organization with a market capitalization of about $60 million, which has constrained it to fly under the radar of financial specialists. In analyst’s assessments, the stock price could increase to $2 in the next year from now, as an aftereffect of income development surpassing estimates.

XXII can quickly be compressed as a plant based biotechnology organization whose mission is to diminish damage brought on by smoking. To adequately do this, the organization has more than 200 licenses in its ownership that give it the capacity to increment or diminishing the level of nicotine in tobacco plants and in addition the level of cannabinoids in cannabis plants. The organization’s principle items include:

RED SUN and MAGIC cigarettes – These are super premium estimated cigarette brands accessible in both normal and menthol available to be purchased in the U.S.

SPECTRUM cigarettes – These are government supported cigarettes with altered levels of nicotine (from low to high) created under an agreement concurrence with the National Institute of Drug Abuse (NIDA). They are circulated to mainstream researchers complimentary to learn the impacts of shifted nicotine levels in cigarettes.

BRAND A and BRAND B – These two cigarette brands are relied upon to be the initially adjusted danger tobacco items (MRTP) to go into conveyance ought to the FDA favor XXII’s application.

X-22 smoking cessation aid – This is a tobacco-based plant restorative item for use as a guide to smoking suspension. The X-22 treatment convention requires the patient to smoke XXII’s low nicotine (VLN) cigarettes over a six-week treatment period to encourage the objective of the patient stopping smoking before the end of the treatment time frame.

The company’s stock currently trades around $1.05 a share. Its outstanding shares are standing around 76,009,960, while authorized shares at 300,000,000.

The Federal Reserve Is Paying Banks NOT To Lend 1.8 Trillion Dollars To The American People … https://t.co/H6Yw4uR8se

The Federal Reserve Is Paying Banks NOT To Lend 1.8 Trillion Dollars To The American People … https://t.co/vrBoLCaUkP

The Federal Reserve Is Paying Banks NOT To Lend 1.8 Trillion Dollars To The American People … https://t.co/qMhfde7ef8

The Federal Reserve Is Paying Banks NOT To Lend 1.8 Trillion Dollars To The American People … https://t.co/I8XU5kkOUK

KDSKF Koninklijke DSM NV https://t.co/R5OMi9qIrs https://t.co/6nvCBvLt3d

Load More...

Share This: